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INTRODUCTORY PARAGRAPH/ABSTRACT: 1 
Medical devices are an integral part of therapeutic management; despite their 2 
importance, they carry a significant risk of microbial infection.  Bacterial attachment to a 3 
medical device is established by a single, multiplying organism, leading to subsequent 4 
biofilm formation.  To date, no preventative measures have impacted the incidence of 5 
device-related infection.  We report the bidirectional covalent coupling of an engineered 6 
cationic antimicrobial peptide (eCAP), WLBU2, to various biological surfaces is 7 
accomplished.  These surfaces included (i) a carbohydrate-based gel matrix, (ii) a 8 
complex polymeric plastic bead, and (iii) a silica-calcium phosphate nanocomposite 9 
associated with bone reconstruction. WLBU2-conjugated surfaces are shown to retain 10 
potent antimicrobial activity related to bacterial surface adhesion.  This study provides 11 
proof of principle that covalently coating laboratory and bone-regenerating materials 12 
with eCAPs has the potential for decreasing infection rates of implanted devices. These 13 
findings have important consequences to the patient management component of our 14 




Cationic antimicrobial peptides (CAPs) have been proposed as an alternative 2 
therapeutic for the management of microbial infection.  With multidrug resistant 3 
pathogens becoming more common, CAPs offer an attractive option to our existing 4 
conventional antibiotics.   CAPs have evolved to be part of the innate immune system 5 
and have a wide spectrum which includes Gram-positive and negative bacteria, viruses 6 
and fungi1-3.   As such, CAPs are proven antimicrobial substances that have been an 7 
untapped source of therapeutics2.  8 
CAPs are expressed in many forms and in different host environments4.  These 9 
can be broadly categorized into three distinct structural motifs—α-helix, β-sheet, and 10 
structurally constrained peptides.   All have the unifying characteristic of presenting a 11 
cationic face on opposite sides of the structure from a hydrophobic face5. The 12 
mechanism by which CAPs accomplish their antimicrobial activity is under debate6.  Not 13 
in dispute is that CAPs are membrane disruptive, and they have a particular selectivity 14 
for the unique composition of bacterial membranes2,7.  Reports from our laboratory have 15 
advanced the CAP field by developing a de novo derived class referred to as 16 
engineered CAPs (eCAPs)3, 8-11.  We have demonstrated that membrane perturbation is 17 
the major mechanism by which eCAPs function11.   Further, our studies have shown that 18 
treatment of bacterial biofilms with exogenous eCAPs reduces bacterial burden12.    19 
The membrane-active properties of eCAPs provide a compelling rationale for 20 
investigating the antimicrobial activity of these reagents bound to an inert surface. This 21 
activity could lead to decreased in adhesion and subsequent inhibition of bacterial 22 
biofilm formation on medical devices.  The implications of such surface-active 23 
antimicrobial activity would have a significant impact on the medical device industry.  24 
 4
For example, intravenous catheters (IVC), bone reconstitution, prosthetic joints, heart 1 
valves, cardiac pacemakers and cerebrospinal fluid shunts have become essential to 2 
the medical field13 and in every case are at risk for infections.  In each of these, 3 
nucleation with progression to biofilm formation on the medical device  is considered the 4 
basis for  systemic infection13,14.    As a result, disrupting the potential nucleation on a 5 
device will disrupt the natural progression to disease (Figure 1). 6 
 7 
RESULTS AND DISCUSSION 8 
Activity of bound WLBU2 to a carbohydrate-based gel matrix through the 9 
free amino group:   Affigel, a carbohydrate-based gel matrix, was used to couple 10 
WLBU2 through the primary amino group on the N-terminus.  The conjugation rate to 11 
the slurry Affigel resin was determined to be 98.9% of available WLBU2 by HPLC and 12 
the calculated concentration of bound peptide was estimated to be 20 µg/mL of resin.  13 
In order to test the antimicrobial properties retained by WLBU2 attached to surfaces, 14 
Pseudomonas aeruginosa strain PA01 was filtered through an Affigel column without 15 
significant effect on the subsequent growth of PA01 (Figure 2a).  The identical inoculum 16 
was filtered through an Affigel-WLBU2 column and three to five colony forming units 17 
(cfu) survived after an overnight incubation.  This represents a five-log difference when 18 
compared to the control group.  The Affigel-WLBU2 column remained effective in two 19 
additional tests with identical results.  However, with additional testing a ten-fold 20 
increased in bacterial survival was seen, indicating that the activity of the Affigel-WLBU2 21 
column was reduced upon repeated exposure, either via digestion or masking of the 22 
peptide.  The activity of the Affigel-WLBU2 column could be regenerated to baseline 23 
with methanol wash.  Understanding the role of Staphylococcal spp in infections related 24 
 5
to medical devices, experiments were performed using Staphylococcus aureus and a 1 
three-log difference was seen compared to the control group. 2 
 3 
Activity of WLBU2 bound to a complex polymer plastic bead through the 4 
carboxyl terminus:  Having assessed the activity of N-terminal coupling of WLBU2, we 5 
next assessed the activity of C-terminal binding to surfaces.  WLBU2 was synthetically 6 
built on a polymeric plastic bead via the free carboxyl group.  Analysis of the Tentagel 7 
beads indicated that the substitution rate was 390 mg/g resin.  As depicted in Figure 2b, 8 
the WLBU2 coupled beads were able to sterilize the PA01 suspension.  The 9 
comparison group with Tentagel beads alone revealed no difference in the survival of P. 10 
aeruginosa when compared to a media control group.  This represents a five-log 11 
difference in survival between the groups post exposure. 12 
To determine that antimicrobial activity seen was a result of WLBU2 leeching, a 13 
Transwell permeable support system was used.  Tentagel-WLBU2 beads placed in the 14 
upper compartment showed no difference in the growth of PA01 in the lower 15 
compartment when compared to a control group without beads (Figure 2b).  Uncoupled 16 
Tentagel beads in suspension with PA01 did not have an affect on the growth of PA01, 17 
while the Tentagel-WLBU2 beads were able to sterilize the PA01 suspension.  The 18 
coupled Tentagel-WLBU2 suspension with PA01 showed a five-log difference 19 
compared to the media, uncoupled and leeching control groups.  These data 20 
demonstrate that physical interaction between the coupled WLBU2 and PA01 is 21 
required for the antimicrobial property.  It also demonstrates that the antimicrobial 22 
properties are not attributable to uncoupled WLBU2. 23 
Activity of WLBU2 associated to a complex a silica-calcium phosphate 24 
nanocomposite associated with bone reconstruction.  A novel resorbable bioactive 25 
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porous silica-calcium phosphate nanocomposite (SCPC) that has the ability to stimulate 1 
bone regeneration and graft material resorption in vivo has been proposed15.   WLBU2’s 2 
antimicrobial activity when incorporated into SCPC was evaluated.  Comparison of the 3 
SCPC alone versus SCPC-WLBU2 composite material was performed by adding 10 mg 4 
of either of these preparations to a 1.5mL tube containing 1x106 P. aeruginosa strain 5 
PA01 in one mL of PBS.  When static incubation (i.e., no agitation) was applied to the 6 
SCPC-WLBU2 minimal killing was achieved after a one hour (not shown).  However, 7 
when agitation was included in the protocol, the bacterial suspension was completely 8 
sterilized signifying a five-log decrease in bacterial survival.  This reinforces that contact 9 
between the coupled WLBU2 and bacterial targets is necessary for effective killing.  10 
Scanning electron microscopy (SEM) was used to visually assess these beads.  Using 11 
the identical bacterial suspensions, it was surprising to see that no bacteria were 12 
attached to the surface of the SCPC (Figure 3a).  However, the SCPC-WLBU2 material 13 
had bacteria associated to the surface even though bacterial growth was negative 14 
(Figure 3b).  In data not shown, we determined that these bacteria were being lysed in 15 
the composite experiment through measurement of beta-galactosidase (an intracellular 16 
bacterial enzyme) released11.   These data support our contention that the positively 17 
charged peptide recruits the bacteria to the surface of the bead, resulting in the lysis of 18 
the bacteria6,16. 19 
In the past, CAP application has been limited to a secondary role with respect to 20 
their inability to demonstrate efficacy in clinical trials6.  However in view of the current 21 
antimicrobial resistance crisis, CAPs are being considered in a more creative manner 22 
that circumvents their limitations.  A previous report demonstrated that immobilized 23 
polymyxin B binds endotoxin in vitro and in sepsis animal models in vivo16.  This has led 24 
to uses of CAP-impregnated fibers in clinical trials for the treatment of sepsis16.  Other 25 
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applications which have been explored include the coating of urinary catheters to 1 
decreased biofilm formation17.  Polymyxin B bound to agarose beads also inhibited E. 2 
coli growth in a concentration dependent curve18.  Antibiotic loaded microspheres have 3 
been attempted to provide local treatment for osteomyelitis15,19.  These strategies 4 
reduce the exposure of CAPs to bacterial proteases18.  We have (i) previously shown 5 
that WLBU2 has greater antimicrobial activity than polymyxin B, (ii) works against a 6 
broader spectrum of Gram positive and negative bacteria, and (iii) will be more effective 7 
than polymyxin B9,11. 8 
Devices such as prosthetic joints, prosthetic heart valves, cardiac pacemakers, 9 
IVC and cerebrospinal fluid shunts have become essential in the medical field13.  10 
However, these medical devices are at risk for infection and impact the rate of 11 
nosocomial infections.  Unlike IVC infections, most foreign body-related infections 12 
require surgical removal.  It is estimated that the United States averages between 13 
200,000 to 400,000 catheter related infection (CRI) per year13, 20.  In patients with long 14 
term need of intravenous access, systemic as well as antibiotic lock therapy may be 15 
implemented to salvage a catheter13.  Biofilm formation on biomedical surfaces is 16 
considered the basis for infection13,14.  Initial bacterial adherence is considered essential 17 
for the formation of biofilm on catheter surfaces13,14.  CRIs can be difficult to treat in part 18 
due to higher minimal inhibitory concentration exhibited by pathogens in the biofilm1,17. 19 
 Reduction of biofilm formation can have a great impact in infection rates that 20 
stem from prosthetics and CRI.  In the past, strategies to reduce biofilm formation 21 
included silver impregnated catheters; however, leaching leaves these materials 22 
vulnerable to bacterial adherence.  The concept of an antimicrobial peptide as a means 23 
to reduce or prevent biofilm formation is feasible. The permanent covalent attachment of 24 
WLBU2 to various surface while retaining its previously demonstrated antimicrobial 25 
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properties in vivo and in vitro against P. aeruginosa3,8,9.  Tethered peptides need direct 1 
contact with the bacteria in order to have effective killing.  As can be seen in the SEM 2 
images (Figure 3b), the bacteria are attracted to the WLBU2 coupled to the 3 
nanocomposite.  The lack of growth from samples obtained provides evidence of 4 
bacterial lysis.  The implications from these experiments suggest that bound WLBU2 5 
may be effective in the prevention of bacterial biofilm formation by reduction of bacterial 6 
survival post contact with WLBU2 coupled material.  These findings have implications 7 
for understanding the surface-active mechanism of WLBU2 action and have 8 
translational health applications for antimicrobial coating of medical devices. 9 
Materials and Methods: 10 
Preparation of bacteria.  Luria broth (LB) was inoculated with a colony of P. aeruginosa 11 
(strain PA01) and incubated overnight at 37ºC with shaking. The next morning, 5mL of 12 
the overnight culture was transferred into 20mL of LB broth and incubated for another 2 13 
hours at 37ºC with shaking. 10mL of the second incubation culture was pelleted and 14 
suspended in 10mL of phosphate buffered saline (PBS) at pH of 7.8. The A600 of the 15 
suspended bacterial solution was read, and the solution was further diluted to a 16 
concentration with an A600=0.001 in PBS.   The S. aureus strain used in this study has 17 
been described previously publications3 and was prepared identically as described for 18 
the P. aeruginosa strain above. 19 
WLBU2 N terminal Coupled to Affigel beads.  A calculated amount of WLBU2 stock 20 
solution was added to 10mL of Affigel resin (Bio-Rad Laboratories) extracted from slurry 21 
to obtain a total concentration of 10µM in the suspension.  A sample of the WLBU2 22 
stock was separated for later comparison.  The manufacturing protocol was followed 23 
under aqueous conditions at room temperature for 2h.  A sample of the supernatant 24 
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was separated and used for analysis of WLBU2 coupling.  After successful attachment 1 
of WLBU2 to Affigel beads (Affigel-WLBU2 beads), a 3cm column was generated.  The 2 
column was washed with PBS prior to running a PA01 bacterial suspension prepared as 3 
described previously.  The resulting suspension was plated, incubated overnight at 37ºC 4 
and colony forming units (cfu) determined. 5 
Analysis of WLBU2 coupled to Affigel beads.  The extent of coupling of WLBU2 to the 6 
Affigel beads was monitored by Reversed phase HPLC analysis of the reaction media 7 
both before and after conjugation.  The analysis was performed using a Waters Alliance 8 
2695 chromatography system and a Waters 2487 Dual Absorbance Detector. Samples 9 
were injected onto a Phenomenex Gemini 5μ C-18 column (250 x 4.6mm) and eluted 10 
with solvent A (0.1%TFA in H2O) and solvent B (0.08% TFA in acetonitrile) at a flow rate 11 
of 1mL/min.  Peak detection at 220nm was followed by data acquisition and integration 12 
using a Waters Empower software package.  The amino acid composition of the 13 
agarose beads generated a high degree of background noise as described by Palate et 14 
al21.  To estimate the substitution rate, the HPLC peaks of the samples obtained pre and 15 
post coupling were compared. 16 
WLBU2 C terminal Coupled to Tentagel beads.  WLBU2 Tentagel beads were 17 
synthesized on an Applied Biosystems 433A peptide synthesizer using standard FMOC 18 
chemistry and 0.25mM FastMoc cycles.  Chain elongation was in stepwise fashion on 19 
TentaGel S NH2 resin (Peptides International) using FMOC protected amino acid 20 
derivatives (Peptides International) containing side-chain protecting groups.  Removal of 21 
the side chain protecting groups was accomplished using standard TFA 22 
(TFA:Triisopropylsilane:H2O) cleavage conditions. This involved treatment of the fully 23 
side chain protected peptide resins with cleavage reagents at a concentration of 24 
20ml/gm for 4h at room temperature. The WLBU-2 TentaGel beads were then filtered 25 
 10
through a Buchner funnel, washed with neat TFA and dried under vacuum.  The dried 1 
beads were suspended in N,N dimethylformamide (DMF), initially washed with DMF 2 
followed by Dichloromethane  and allowed to air dry. 3 
Analysis of carboxy terminal WLBU2 coupled to Tentagel beads.  After completion of 4 
hydrolysis of WLBU2 Tentagel beads, the samples were completely dried under 5 
vacuum. Samples were suspended in 60% acetonitrile/0.1%TFA in H2O and sonicated 6 
for 20minutes. The supernatant was dried under vacuum and suspended in 20mM HCL, 7 
followed by derivitization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate using 8 
Waters AccQ·Tag analysis kit.  Samples were analyzed by chromatography using 9 
standard gradient conditions.  Fluorescence detection at an excitation wavelength of 10 
250nm was used to acquire integration peaks.  11 
Binding of WLBU2 to Silica-Calcium Phosphate Nanocomposite.  Resorbable porous 12 
bioactive SCPC with the chemical composition was prepared by heating at 850°C.  13 
Appropriate ratios of dicalcium phosphate and silicon components were placed in 14 
polyethylene bottles and mixed on a roller mixer for 24h. The batch was moistened with 15 
0.1 NaOH and placed in a Teflon mold. The samples were left to dry at room 16 
temperatures and then thermally treated (Thermolyne 30400, Barnstead International, 17 
Dubuque, IA) at 850°C for 1h. The heating temperature was selected based on the 18 
differential thermal analysis results previously reported15. The SCPC ceramic was 19 
ground, sifted and immersed in simulated body fluid at 37°C for 16h. After immersion 20 
the samples were dried and the surface chemistry and morphology were analyzed by 21 
Fourier transform infrared spectroscopy (FTIR) and Scanning Electron Microscope-22 
Energy Dispersive X-Ray (SEM-EDX) analyses, respectively. The SCPC particles were 23 
loaded with WLBU2 using immersion method15 and dried. 24 
 11
Peptide Leaching. To evaluate potential leaching of the peptide being responsible for 1 
the antimicrobial activity of the bound CAP, a Transwell protein migration system was 2 
used.  Bacteria was prepared as above to achieve an A600=0.001 in PBS.  Ten 3 
milligrams of Tentagel beads as well as Tentagel-WLBU2 beads were weighed 4 
individually.  Triplicate wells in a 96 well plate were set up by adding 600 µL of the 5 
bacterial solution for all of the following groups.  The first group had bacterial 6 
suspension added to the lower compartment and Tentagel-WLBU2 coated beads added 7 
to the upper compartment of the insert.  The second group had bacterial suspension 8 
added to the lower compartment and Tentagel beads placed in the upper compartment 9 
of the insert.  The third group had Tentagel beads to which bacterial suspension was 10 
added.  The fourth group had Tentagel-WLBU2 coated beads to which bacterial 11 
suspension was added.  Initially, the plate was rested at 37ºC, but it was there was no 12 
difference between the four groups.  A simple agitation was incorporated to the protocol 13 
and the described results were obtained.  The plate was agitated at 37ºC and each 14 
group was subsequently plated to count cfu after overnight incubation at 37ºC. To asses 15 
the effect of agitation a control group consisting of PA01 suspension alone was used as 16 
baseline for bacterial growth. 17 
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Figure Legends: 1 
Figure 1.  Illustration demonstrating coupled peptide to a surface disrupting 2 
bacterial cell membrane.   Coating surfaces with these peptides is a strategy to 3 
prevent bacterial attachment and subsequent biofilm formation. 4 
Figure 2.  Panel depicting the bidirectional coupled antimicrobial properties of 5 
WLBU2 and leeching experiments.  (a) P. aeruginosa was filtered through Affigel 6 
alone and Affigel-WLBU2 columns revealing decreased survival of bacteria exposed to 7 
coupled beads. Overnight incubation revealed no growth of P. aeruginosa after 8 
Tentagel-WLBU2 exposure when compared to Tentagel beads alone. (b) Transwell 9 
protein migration system was used to demonstrate that the antimicrobial activity of 10 
coupled Tentagel-WLBU2 was not attributable to free WLBU2 in solution. The 11 
membrane pore size prevented Tentagel beads from migrating but would have allowed 12 
uncoupled WLBU2 to cross into the bacterial suspension. 13 
 Figure 3. Scanning electron microscopy (SEM) analysis of P. aeruginosa 14 
exposed to SCPC alone or SCPC-WLBU2 composite. (a) SEM demonstrating no P. 15 
aeruginosa on the surface of the SCPC nanocomposite without coupling. (b) The 16 
SCPC-composite demonstrates bacteria associated with the nanocomposite surface 17 
and also demonstrates bacterial lysis. 18 
 13
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